SGHT · CIK 0001531177 · operating
Sight Sciences develops and commercializes surgical and nonsurgical ophthalmic devices focused on treating prevalent eye diseases. The company operates primarily in two segments: Surgical Glaucoma and Dry Eye. Its surgical glaucoma portfolio includes the OMNI system, an implant-free, handheld device that enables surgeons to perform comprehensive procedures to reduce intraocular pressure in patients with primary open-angle glaucoma through catheterization and viscodilation of Schlemm's canal and trabecular meshwork cutting. The company also offers the SION surgical instrument, a manually operated device designed for trabecular meshwork excision. In the dry eye segment, Sight Sciences provides the TearCare system, which targets meibomian gland obstruction by melting obstructions and restoring gland functionality.
The company distributes its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals throughout the United States. Sight Sciences operates with approximately 216 full-time employees and maintains its headquarters in Menlo Park, California. The company was incorporated in Delaware in 2010.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.03 | $-1.03 | +9.6% | |
| 2023 | $-1.14 | $-1.14 | +36.7% | |
| 2022 | $-1.80 | $-1.80 | — | |
| 2021 | — | — | — |